 Editas Medicine Inc NASDAQ: EDIT has announced initial clinical data from the ongoing Phase 12 BRILLIANCE trial of EDIT-101 for blindness due to Leber congenital amaurosis 10 LCA10, a CEP290-related retinal degenerative disorder. Related Link: Editas Medicine Unveils Preclinical Data From New Gene Editing Technology. 